ORIGIN OF MOLECULAR BIOMARKERS Models of metastasis indicate that primary tumor cells spread to other organs via blood circulation. Sensitive detection of occult carcinoma cells in the peripheral blood of CRC patients has important prognostic and therapeutic implications. Such neoplastic cells may be present in the bloodstream in very low numbers and would hardly be detected by conventional methods. With recent developments in molecular technology, the use of PCR, reverse transcription-PCR (RT-PCR), or real-time quantitative-PCR (QPCR) assays now permit sensitive detection of circulating tumor cells (CTC) in peripheral blood. Cancer cells often have gene expression patterns distinct from normal tissues. This difference can be used diagnostically through detecting the tumor-specific transcripts in blood samples of cancer patients. Molecular biomarker profiles can be obtained from circulating cells and peripheral blood cells, plasma or serum as well as other body fluids for identifying asymptomatic individuals at risk. BioMarCare Technologies focuses on testing for cancer-related nucleic acids derived from plasma of a patient suspected to have cancer or screen for cancer. The combined testing for levels of several RNA markers is used to ensure high sensitivity and specificity of the test.